Virbac cuts revenue forecast on U.S., Chile market conditions
Sept 19 (Reuters) - French veterinary pharmaceutical firm Virbac reported a jump in first-half earnings on Monday but trimmed its 2016 revenue growth forecasts due to difficulties in the United States and Chile, as well as a negative currency impact.
The company, which sells drugs for animals in more than 100 countries, is now aiming for organic revenue growth of 4.5-6.5 percent in 2016 compared with a previous target of 7 percent, it said in a statement.
The company's adjusted current operating profit rose 44.8 percent to 39.7 million euros in the first half, helped by an improved performance by its U.S. subsidiary. (Reporting by Alan Charlish; editing by David Clarke)
© Thomson Reuters 2017 All rights reserved.